Ryanodine Receptor 3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ryanodine receptor 3 (RyR3) is the most widely distributed isoform of the ryanodine receptor family, expressed in numerous tissues including skeletal muscle, brain, heart, and other organs. While RyR1 is the predominant isoform in skeletal muscle and RyR2 dominates in cardiac muscle, RyR3 is expressed at lower levels in both and can compensate for loss of other isoforms. In the brain, RyR3 is prominently expressed in the hippocampus, cortex, and cerebellum, where it participates in neuronal calcium signaling, synaptic plasticity, and memory formation. RyR3 is particularly important in hippocampal CA1 pyramidal neurons where it contributes to long-term potentiation (LTP). Studies suggest RyR3 may play roles in learning and memory, and its dysregulation has been implicated in neurodegenerative diseases including Alzheimer's disease and psychiatric disorders.
| Ryanodine Receptor 3 Protein | |
|---|---|
| Protein Name | Ryanodine Receptor 3 Protein |
| Gene | RYR3 |
| UniProt ID | Q15413 |
| PDB IDs | N/A (homology model) |
| Molecular Weight | 560 kDa |
| Subcellular Location | Endoplasmic/sarcoplasmic reticulum |
| Protein Family | Ryanodine receptor family |
Ryanodine Receptor 3 Protein is a Ryanodine receptor family. This protein contains characteristic transmembrane domains and regulatory domains that control channel activity and calcium release.
RYR3 is the third ryanodine receptor isoform with widespread but lower expression than RYR1/RYR2. RYR3 may function as a calcium leak channel and modulate calcium signaling in various tissues. In the brain, RYR3 is expressed in hippocampal neurons and may contribute to synaptic plasticity and calcium homeostasis. It has distinct regulatory properties from RYR1/RYR2.
RYR3 alterations are found in AD brains, bipolar disorder, and epilepsy. RYR3 may compensate for RYR1/RYR2 dysfunction in some contexts.
No specific RYR3-targeted drugs are available. General ryanodine receptor modulators may affect RYR3.
The study of Ryanodine Receptor 3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.